Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections

Clinical Infectious Diseases

Volumn 59, Issue 3, 2014, Pages 358-365

  Carapetis, Jonathan R ^a   Jacoby, Peter ^a   Carville, Kylie ^b   Ang, Seong Jin Joel ^c   Curtis, Nigel ^c   Andrews, Ross ^d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

Clindamycin; Contact; Immunoglobulin; Mortality; Streptococcal

Indexed keywords

ANTIINFECTIVE AGENT; CLINDAMYCIN; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; AGED; CHILD; DRUG EFFECTS; FASCIITIS, NECROTIZING; FEMALE; HEALTH SURVEY; HUMAN; INCIDENCE; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PRESCHOOL CHILD; PROSPECTIVE STUDY; RISK; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; VERY ELDERLY; VICTORIA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINDAMYCIN; FASCIITIS, NECROTIZING; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; VICTORIA; YOUNG ADULT;

EID: 84904972009     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu304     Document Type: Article

References (31)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5: 685-94.
2. O'Brien KL, Beall B, Barrett L, et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. Clin Infect Dis 2002; 35: 268-76.
3. Stevens DL Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995; 1: 69-78.
4. Allen U, Moore D. Invasive group A streptococcal disease: management and chemoprophylaxis. Paediatr Child Health 2010; 15: 295-302.
5. Antibiotic Expert Group. Therapeutic guidelines: antibiotic. Version 13, 2006. North Melbourne: Therapeutic Guidelines Limited, 2006.
6. American Academy of Pediatrics Committee on Infectious Diseases. Severe invasive group A streptococcal infections: a subject review. Pediatrics 1998; 101: 136-40.
7. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158: 23-8.
8. Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993; 167: 1401-5.
9. Mascini EM, Jansze M, Schouls LM, Verhoef J, Van Dijk H. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents 2001; 18: 395-8.
10. Goscinski G, Tano E, Thulin P, Norrby-Teglund A, Sjolin J. Release of SpeA from Streptococcus pyogenes after exposure to penicillin: dependency on dose and inhibition by clindamycin. Scand J Infect Dis 2006; 38: 983-7.
11. Sawai J, Hasegawa T, Kamimura T, et al. Growth phase-dependent effect of clindamycin on production of exoproteins by Streptococcus pyogenes. Antimicrob Agents Chemother 2007; 51: 461-7.
12. Sriskandan S, McKee A, Hall L, Cohen J. Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother 1997; 40: 275-7.
13. Mulla ZD, Leaverton PE, Wiersma ST. Invasive group A streptococcal infections in Florida. South Med J 2003; 96: 968-73.
14. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999; 18: 1096-100.
15. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 333-40.
16. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28: 800-7.
17. Norrby-Teglund A, Muller M, McGeer A, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005; 37: 166-72.
18. Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 2009; 49: 1369-76.
19. Basma H, Norrby-Teglund A, McGeer A, et al. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect Immun 1998; 66: 2279-83.
20. Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 1998; 26: 631-8.
21. Roy S, Schreiber JR, John CC, et al. A family cluster of five cases of group A streptococcal pneumonia. Pediatrics 2003; 112: 61-5.
22. Public Health Agency of Canada. Guidelines for the prevention and control of invasive group A streptococcal infections. CCDR 2006; 32: 1-26.
23. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996; 335: 547-54.
24. Steer JA, Lamagni T, Healy B, et al. Guidelines for prevention and control of group A streptococcal infection in acute healthcare and maternity settings in the UK. J Infect 2012; 64: 1-18.
25. Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis 2002; 35: 950-9.
26. Health Protection Agency, Group A Streptococcus Working Group. Interim UK guidelines for management of close community contacts of invasive group A streptococcal disease. Commun Dis Public Health 2004; 7: 354-61.
27. O'Grady KA, Kelpie L, Andrews R, et al. The epidemiology of invasive groups A streptococcal disease in Victoria, Australia. Med J Aust 2007; 186: 565.
28. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA 1993; 269: 390-1.
29. Thomas KS, Crook AM, Nunn AJ, et al. Penicillin to prevent recurrent leg cellulitis. N Engl J Med 2013; 368: 1695-703.
30. Australian Bureau of Statistics. Year Book Australia 2012. Canberra: Australian Bureau of Statistics, 2012.
31. Rogers S, Commons R, Danchin MH, et al. Strain prevalence, rather than innate virulence potential, is the major factor responsible for an increase in serious group A streptococcus infections. J Infect Dis 2007; 195: 1625-33.